Eventide Asset Management’s Novavax NVAX Stock Holding History

Eventide Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-72,485	Closed	-$1.83M	–	127
2016 Q4	$1.83M	Sell	72,485 -36,500	-33%	-$1.06M	0.12%	95
2016 Q3	$4.53M	Hold	108,985	–	–	0.28%	71
2016 Q2	$15.8M	Hold	108,985	–	–	0.97%	40
2016 Q1	$11.2M	Hold	108,985	–	–	0.63%	53
2015 Q4	$18.3M	Buy	108,985 +4,110	+4%	+$633K	0.91%	44
2015 Q3	$14.8M	Buy	104,875 +9,440	+10%	+$2.12M	0.86%	44
2015 Q2	$21.3M	Hold	95,435	–	–	1.15%	38
2015 Q1	$15.8M	Hold	95,435	–	–	1.19%	34
2014 Q4	$11.3M	Hold	95,435	–	–	1.24%	32
2014 Q3	$7.96M	Hold	95,435	–	–	1.11%	39
2014 Q2	$8.82M	Buy	95,435 +8,390	+10%	+$737K	1.2%	40
2014 Q1	$7.89M	Buy	87,045 +22,680	+35%	+$2.53M	1.22%	38
2013 Q4	$6.59M	Buy	+64,365	New	+$4.55M	2.03%	17

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eventide Asset Management's NVAX Position: Q1 2017 in Review

Eventide Asset Management sold out of Novavax (NVAX) in Q1 2017, closing a stake of 72,485 shares — an estimated $1.83M sold.

Eventide Asset Management first reported a position in NVAX in Q4 2013 and held it in 13 quarters. The position peaked at $21.3M in Q2 2015. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

Eventide Asset Management reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
Eventide Asset Management sold 72,485 Novavax shares in Q1 2017, an estimated $1.83M.
Eventide Asset Management first reported a position in Novavax in Q4 2013 and held it in 13 quarters.
Eventide Asset Management's Novavax position peaked at $21.3M in Q2 2015.
129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Eventide Asset Management's 13F filing for Q1 2017, filed 15 May 2017.